Lates News

GSK announced that in patients with platinum-resistant ovarian cancer, the morez therapy achieved a median progression-free survival of 11.1 months. GSK also announced that in the ovarian cancer trial, the confirmed objective response rate for the morez therapy was 62%, with a median duration of response of 12.2 months.